OncoMatch/Clinical Trials/NCT05990751
Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma
Is NCT05990751 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies GD2 CAR T cells for neuroblastoma.
Treatment: GD2 CAR T cells — MAGNETO is a single-centre, non-randomised, open label Phase I clinical trial of an Advanced Therapy Investigational Medicinal Product (ATIMP) in children and teenagers aged 1-16 years with relapsed or refractory neuroblastoma. The study will assess the feasibility of generating the ATIMP (GD2 CAR T cells) and the safety of administering the ATIMP in patients with relapsed or refractory neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroblastoma
Biomarker criteria
Allowed: GD2 overexpression
If sufficient biopsy material is available, GD2 expression on the tumour will be confirmed. As GD2 is consistently expressed in neuroblastoma demonstration of GD2 is not mandated.
Prior therapy
Must have received: salvage combination chemotherapy
Disease which has relapsed after or is refractory to at least one line of salvage combination chemotherapy
Cannot have received: gene therapy
Prior treatment with investigational or approved gene therapy or cell therapy products
Cannot have received: cell therapy
Prior treatment with investigational or approved gene therapy or cell therapy products
Lab requirements
Blood counts
absolute lymphocyte count ≥ 0.25 x 10^9/l
Kidney function
creatinine ≤1.5 uln for age, if higher, an estimated (calculated) creatinine clearance must be ≥ 60 ml/min/1.73 m2
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify